Compare APWC & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APWC | XLO |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.1M | 39.4M |
| IPO Year | 1997 | 2021 |
| Metric | APWC | XLO |
|---|---|---|
| Price | $1.62 | $0.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 6.0K | ★ 417.7K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,344,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | $12.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.45 | $0.50 |
| 52 Week High | $2.34 | $1.18 |
| Indicator | APWC | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 37.30 | 49.01 |
| Support Level | $1.56 | $0.51 |
| Resistance Level | $1.75 | $0.61 |
| Average True Range (ATR) | 0.01 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 7.14 | 60.94 |
Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in the manufacture and distribution of enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, PRC, Hong Kong and certain other markets in the Asia Pacific region. It also provides project engineering services in the supply, delivery and installation of power cables (SDI). Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and Rest of the World.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.